In vitro evaluation of bactericidal and bacteriostatic compounds using airway tissues

1. MucilAir™ and SmallAir™, platforms to evaluate many bacterial infections related end points

Respiratory Bacterial infections cause mild to severe diseases worldwide, such as pharyngitis, sinusitis, bronchitis, bronchiolitis and pneumonia, are associated with huge costs for society. To test new molecules for shortening, alleviating the diseases or to develop new therapies, relevant human models are mandatory. MucilAir™ and SmallAir™, holds in vitro specific mechanisms to counter invaders comparable to the in vivo situation, such as mucus production, mucociliary clearance, and secretion of defensive molecules.

Contract us to evaluate the efficiency of your novel anti bacterial coumpounds on the following strains:

Pseudomonas Aeruginosa x	Streptococcus Pneumoniae x
Staphylococcus Aureus x	Haemophilus Influenzae x

2. Testing strategy

3. Efficient Replication of Pseudomonas aeruginosa (PA)

PA growth is slightly inhibited by presence of Mucus as efficiently inhibited by Meronem treatment.

4. Cytotoxicity induced by Pseudomonas Aeruginosa

Mucus seemed to prevent cytotoxicity induced by PA up to 72h. Meronem prevented cytotoxicity induced by PA up to 72h

5. Evaluation of barrier function after PA infection

PA impaired the barrier function from 48h post inoculation without mucus. Presence of mucus protect the barrier function up to 48h. Meronem efficiently preserved the barrier function from PA infection at all tested time points.

More information: Please contact